Free Trial

RxSight Q1 2024 Earnings Report

RxSight logo
$33.66 -4.53 (-11.86%)
(As of 12/20/2024 05:31 PM ET)

RxSight EPS Results

Actual EPS
-$0.25
Consensus EPS
-$0.17
Beat/Miss
Missed by -$0.08
One Year Ago EPS
-$0.42

RxSight Revenue Results

Actual Revenue
$29.51 million
Expected Revenue
$27.56 million
Beat/Miss
Beat by +$1.95 million
YoY Revenue Growth
+68.70%

RxSight Announcement Details

Quarter
Q1 2024
Time
After Market Closes

Conference Call Resources

Conference Call Audio

Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong (Ad)

Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.

Click here to watch this demo and decide for yourself.

RxSight Earnings Headlines

Forecasting The Future: 4 Analyst Projections For RxSight
Stifel Downgrades RxSight (RXST)
Could This Tiny Device Help You Make an Extra $30k a Year?
I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.
Wells Fargo Downgrades RxSight (RXST)
See More RxSight Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like RxSight? Sign up for Earnings360's daily newsletter to receive timely earnings updates on RxSight and other key companies, straight to your email.

About RxSight

RxSight (NASDAQ:RXST), a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

View RxSight Profile

More Earnings Resources from MarketBeat

Upcoming Earnings